Aaron Kantoff's most recent trade in Tourmaline Bio Inc was a trade of 88,281 Common Stock done . Disclosure was reported to the exchange on Oct. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tourmaline Bio Inc | Aaron Kantoff | Director | 28 Oct 2025 | 88,281 | 0 | - | - | Common Stock | ||
| Tourmaline Bio Inc | Aaron Kantoff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Oct 2025 | 16,800 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Oct 2025 | 10,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Oct 2025 | 5,000 | 88,281 | - | 0 | Common Stock | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2025 | 37,890 | 0 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.13 per share. | 05 Sep 2025 | 37,890 | 83,281 | - | 0.1 | 4,926 | Common Stock |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.46 per share. | 05 Sep 2025 | 10,000 | 93,281 | - | 9.5 | 94,600 | Common Stock |
| Avalo Therapeutics Inc | Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,100 | 20,100 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 16,800 | 16,800 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 6,333 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Aaron Kantoff | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 3,167 | 3,167 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 24,600 | 24,600 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 9,500 | 9,500 | - | - | Restricted Stock Units | |
| Tourmaline Bio Inc | Aaron Kantoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |